Medical specialists from Japan tagged as investigators in clinical trials studying Fatty Liver

Total 36 results

Atsumasa Komori
Seen in:
- Nagasaki, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05630820 (Principal Investigator)
- NCT05583344 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Atsushi Tagami
Seen in:
- Gifu, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease
Chikara Ogawa
Seen in:
- Kagawa, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease
Hidekatsu Kuroda
Seen in:
- Iwate, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease
Hideki Fujii
Seen in:
- Osaka, Osaka Metropolitan Univ Hosp
Trials:
- NCT04166773 (Principal Investigator)
Conditions:
- Nonalcoholic Steatohepatitis
Hideki Hayashi
Seen in:
- Gifu, GSK Investigational Site
- Gifu, Gifu Municipal Hospital
Trials:
- NCT04166773 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Steatohepatitis;
- Nonalcoholic Fatty Liver Disease
Hidenori Toyoda
Seen in:
- Gifu, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease
Hirokazu Takahashi
Seen in:
- Saga, GSK Investigational Site
- Saga, Saga Medical School Hospital
Trials:
- NCT04166773 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Steatohepatitis;
- Nonalcoholic Fatty Liver Disease
Hiroshi Tobita
Seen in:
- Shimane, GSK Investigational Site
- Shimane, Izumo, Shimane University Hospital
Trials:
- NCT04166773 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Steatohepatitis;
- Nonalcoholic Fatty Liver Disease
Hiroyuki Fukase
Seen in:
- Tokyo, Shinjuku-ku, Clinical Research Hospital Tokyo
Trials:
- NCT04451408 (Principal Investigator)
- NCT05395481 (Principal Investigator)
Conditions:
Kazuo Notsumata
Seen in:
- Fukui, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05630820 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
Keisuke Amano
Seen in:
- Fukuoka, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease
Ken Furuya
Seen in:
- Hokkaido, GSK Investigational Site
- Hokkaido, Sapporo-shi, JCHO Hokkaido Hospital
Trials:
- NCT04166773 (Principal Investigator)
- NCT05630820 (Principal Investigator)
Conditions:
Kenichi Furihata
Seen in:
- Tokyo, Hachioji, P-one clinic
Trials:
- NCT05486208 (Principal Investigator)
- NCT05395481 (Principal Investigator)
- NCT05026866 (Principal Investigator)
- NCT06119529 (Principal Investigator)
Conditions:
Masahiro Kido
Seen in:
- Osaka, Higashi-cho, Hirakata-city, Hirakata kohsai Hospital
Trials:
- NCT04166773 (Principal Investigator)
Conditions:
- Nonalcoholic Steatohepatitis
Masashi Yoneda
Seen in:
- Aichi-ken, Nagakute-shi, Aichi Medical University Hospital
Trials:
- NCT04166773 (Principal Investigator)
Conditions:
- Nonalcoholic Steatohepatitis
Masato Yoneda
Seen in:
- Kanagawa, GSK Investigational Site
- Kanagawa, Yokohama, Yokohama City University Hospital
Trials:
- NCT04166773 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Steatohepatitis;
- Nonalcoholic Fatty Liver Disease
Miwa Kawanaka
Seen in:
- Okayama, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease
Saiyu Tanaka
Seen in:
- Nara-Ken, Nara-Shi, JADECOM Nara City Hospital
Trials:
- NCT04166773 (Principal Investigator)
Conditions:
- Nonalcoholic Steatohepatitis
Seiichi Mawatari
Seen in:
- Kagoshima, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease
Shigetoshi Fujiyama
Seen in:
- Kumamoto, GSK Investigational Site
- Kumamoto, Kumamoto Shinto General Hospital
Trials:
- NCT05630807 (Principal Investigator)
- NCT04166773 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Shogo Shimizu
Seen in:
- Gifu, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease;
- Hepatitis B
Takashi Nakahara
Seen in:
- Hiroshima, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease
Takeji Umemura
Seen in:
- Nagano, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
Takemi Akahane
Seen in:
- Nara, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease
Takeshi Yokoo
Seen in:
- Niigata, Niigata University Medical & Dental Hospital
Trials:
- NCT04166773 (Principal Investigator)
Conditions:
- Nonalcoholic Steatohepatitis
Takuya Nagano
Seen in:
- Kagawa, GSK Investigational Site
Trials:
- NCT05630820 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
Tatehiro Kagawa
Seen in:
- Kanagawa, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
Toshihide Shima
Seen in:
- Osaka, GSK Investigational Site
- Osaka, Suita, Osaka Saiseikai Suita hospital
Trials:
- NCT04166773 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Steatohepatitis;
- Nonalcoholic Fatty Liver Disease
Tsunamasa Watanabe
Seen in:
- Kanagawa, GSK Investigational Site
Trials:
- NCT05583344 (Principal Investigator)
Conditions:
- Nonalcoholic Fatty Liver Disease

Clinical Trials on Fatty Liver

Shiraz University of Medical Sciences

Completed

The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease (ThymeLiv)

Fatty Liver | Fatty Liver, Nonalcoholic

Iran, Islamic Republic of
Hoffmann-La Roche

Completed

A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease

Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD

Germany, Austria
Genfit

Terminated

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Non-Alcoholic Fatty Liver

Netherlands
Medical College of Wisconsin
ENDRA Life Sciences, Inc.

Recruiting

Assessment of Fatty Liver With Thermo-acoustic Device

Fatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver Disease

United States
Cairo University

Recruiting

Calisthenics Versus High Intensity Interval Training in NAFL

Non-Alcoholic Fatty Liver Disease

Egypt
Miriam Vos, MD
Immuron Ltd.; Advanced MR Analytics AB

Completed

Anti-LPS Antibody Treatment for Pediatric NAFLD

Nonalcoholic Fatty Liver Disease (NAFLD)

United States
Nehal Abou Seada

Completed

Efficacy of Phosphatidylcholine in NAFLD

Non-Alcoholic Fatty Liver Disease
HaEmek Medical Center, Israel

Terminated

Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease (FLM)

Patients With Fatty Liver Disease

Israel
AB Biotics, SA

Completed

Efficacy and Safety of a Probiotic Composition as Adjunct in MAFL Management

Non Alcoholic Fatty Liver

Mexico
University of L'Aquila

Recruiting

Study of Neutrophils and Circulating Platelets in Correlation With the Activity of T Lymphocytes in Patients With NAFLD (Nonalcoholic Fatty Liver Disease) (NAFLD)

NAFLD- Non Alcoholic Fatty Liver Disease

Italy

Medical specialists from Japan tagged as investigators in clinical trials studying Fatty Liver

Clinical Trials on Fatty Liver

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations